Last reviewed · How we verify
Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma
This phase I trial studies the side effects and best dose of carfilzomib when given together with the hyperfractionated (hyper)-cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, and dexamethasone (CVAD) chemotherapy regimen in treating patients with newly diagnosed acute lymphoblastic leukemia or lymphoma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving carfilzomib with combination chemotherapy may kill more cancer cells.
Details
| Lead sponsor | Mehrdad Abedi, MD |
|---|---|
| Phase | PHASE1 |
| Status | COMPLETED |
| Enrolment | 10 |
| Start date | Thu Dec 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Jan 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Contiguous Stage II Adult Lymphoblastic Lymphoma
- Noncontiguous Stage II Adult Lymphoblastic Lymphoma
- Stage I Adult Lymphoblastic Lymphoma
- Stage III Adult Lymphoblastic Lymphoma
- Stage IV Adult Lymphoblastic Lymphoma
- Untreated Adult Acute Lymphoblastic Leukemia
Interventions
- carfilzomib
- cyclophosphamide
- vincristine sulfate
- doxorubicin hydrochloride
- dexamethasone
- methotrexate
- cytarabine
- leucovorin calcium
- methylprednisolone
- rituximab
Countries
United States